MLTX Investor Notice: Robbins LLP Reminds Stockholders of the Securities Fraud Class Action Against MoonLake Immunotherapeutics

Core Points - A class action has been filed against MoonLake Immunotherapeutics on behalf of investors who purchased its common stock between March 10, 2024, and September 29, 2025 [1] - The allegations include misleading statements regarding the efficacy of MoonLake's drug candidate SLK compared to the FDA-approved drug BIMZELX [2] - On September 28, 2025, MoonLake announced that SLK failed to demonstrate competitive efficacy relative to BIMZELX, resulting in a significant stock price drop of $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [3] Allegations - The complaint states that MoonLake misled investors about the differences between Nanobodies and monoclonal antibodies, specifically regarding SLK's clinical benefits and efficacy [2] - Key points of the allegations include that SLK and BIMZELX target the same inflammatory cytokines, and that SLK's unique structure does not provide a clinical advantage over BIMZELX [2] Next Steps - Shareholders interested in participating in the class action must submit their papers to the court by December 15, 2025, to serve as lead plaintiff [4] - Shareholders can remain absent class members if they choose not to participate in the case [4]